Development News Edition
Give Feedback

GlaxoSmithKline's two-drug HIV treatment met its main goal

The safety results for the new HIV treatment, a fixed-dose once-daily tablet that combines two previously approved drugs, dolutegravir and rilpivirine, were consistent with the product labelling for the medicines, GSK's majority owned ViiV Healthcare said.


Reuters Last Updated at 14 Jun 2018, 11:06 IST
GlaxoSmithKline's two-drug HIV treatment met its main goal
  • The safety results for the new HIV treatment, a fixed-dose once-daily tablet that combines two previously approved drugs, dolutegravir and rilpivirine, were consistent with the product labelling for the medicines, GSK's majority owned ViiV Healthcare said. (Image Credit: Twitter)

GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies.

The studies were designed to evaluate the safety and efficacy of the two-drug combination, which is aimed at lessening the side effect of current treatments that combine three or four medicines.

The safety results for the new HIV treatment, a fixed-dose once-daily tablet that combines two previously approved drugs, dolutegravir and rilpivirine, were consistent with the product labelling for the medicines, GSK's majority owned ViiV Healthcare said.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


add banner

LEAVE COMMENT

Download our Android App on Google Play